Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios-Athanasios Dimopoulos

Showing results (171-180 of 283) with videos related to

Pageof 29
Sort By:
British Journal of Pharmacology|April 29, 2024
Implications and hidden toxicity of cardiometabolic syndrome and early-stage heart failure in carfilzomib-induced cardiotoxicityPanagiotis Efentakis, Aimilia Varela, Sofia Lamprou, et al.
International Journal of Clinical Oncology|October 31, 2018
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker studyAristotelis Bamias, Vasilios Karavasilis, Nikolaos Gavalas, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 29, 2026
BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal FunctionLudek Pour, Sosana Delimpasi, Wojciech Legiec, et al.
International Journal of Molecular Sciences|July 29, 2023
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple MyelomaIoannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, et al.
Oncotargets and Therapy|August 1, 2015
Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?Aris Giannos, Martin Filipits, Flora Zagouri, et al.
Current Oncology (Toronto, Ont.)|March 27, 2026
Molecular Profiling and Treatment Outcomes in Uterine Serous Carcinoma: Prognostic Role of Estrogen Receptor ExpressionAnna Svarna, Michalis Liontos, Kallirroi Goula, et al.
Blood Cancer Journal|March 16, 2025
Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcomeKonstantinos Soureas, Panagiotis Malandrakis, Maria-Alexandra Papadimitriou, et al.
European Journal of Haematology|May 23, 2023
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapiesDespina Fotiou, Foteini Theodorakakou, Maria Gavriatopoulou, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 19, 2018
Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WMMaria Gavriatopoulou, Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, et al.
International Journal of Molecular Sciences|October 23, 2021
Elucidating Carfilzomib's Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of MetforminPanagiotis Efentakis, Garyfalia Psarakou, Aimilia Varela, et al.
Pageof 29

Showing results (171-180 of 283) with videos related to

Sort By:
Pageof 29
British Journal of Pharmacology|April 29, 2024
Implications and hidden toxicity of cardiometabolic syndrome and early-stage heart failure in carfilzomib-induced cardiotoxicityPanagiotis Efentakis, Aimilia Varela, Sofia Lamprou, et al.
International Journal of Clinical Oncology|October 31, 2018
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker studyAristotelis Bamias, Vasilios Karavasilis, Nikolaos Gavalas, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 29, 2026
BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal FunctionLudek Pour, Sosana Delimpasi, Wojciech Legiec, et al.
International Journal of Molecular Sciences|July 29, 2023
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple MyelomaIoannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, et al.
Oncotargets and Therapy|August 1, 2015
Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?Aris Giannos, Martin Filipits, Flora Zagouri, et al.
Current Oncology (Toronto, Ont.)|March 27, 2026
Molecular Profiling and Treatment Outcomes in Uterine Serous Carcinoma: Prognostic Role of Estrogen Receptor ExpressionAnna Svarna, Michalis Liontos, Kallirroi Goula, et al.
Blood Cancer Journal|March 16, 2025
Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcomeKonstantinos Soureas, Panagiotis Malandrakis, Maria-Alexandra Papadimitriou, et al.
European Journal of Haematology|May 23, 2023
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapiesDespina Fotiou, Foteini Theodorakakou, Maria Gavriatopoulou, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 19, 2018
Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WMMaria Gavriatopoulou, Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, et al.
International Journal of Molecular Sciences|October 23, 2021
Elucidating Carfilzomib's Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of MetforminPanagiotis Efentakis, Garyfalia Psarakou, Aimilia Varela, et al.
Pageof 29